Adverum Biotechnologies (ADVM) News Today $4.93 -0.47 (-8.70%) Closing price 03/25/2025 04:00 PM EasternExtended Trading$4.91 -0.02 (-0.49%) As of 09:19 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Major Shareholder Braden Michael Leonard Purchases 30,600 SharesAdverum Biotechnologies, Inc. (NASDAQ:ADVM - Get Free Report) major shareholder Braden Michael Leonard bought 30,600 shares of the stock in a transaction dated Thursday, March 20th. The shares were bought at an average cost of $5.61 per share, with a total value of $171,666.00. Following the completion of the purchase, the insider now directly owns 2,722,761 shares of the company's stock, valued at approximately $15,274,689.21. This trade represents a 1.14 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Major shareholders that own more than 10% of a company's stock are required to disclose their transactions with the SEC.March 21, 2025 | marketbeat.comInsider Buying: Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Major Shareholder Purchases 62,341 Shares of StockAdverum Biotechnologies, Inc. (NASDAQ:ADVM - Get Free Report) major shareholder Braden Michael Leonard purchased 62,341 shares of the business's stock in a transaction on Tuesday, March 18th. The shares were acquired at an average cost of $4.69 per share, with a total value of $292,379.29. Following the acquisition, the insider now directly owns 2,667,161 shares in the company, valued at approximately $12,508,985.09. The trade was a 2.39 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Major shareholders that own more than 10% of a company's stock are required to disclose their sales and purchases with the SEC.March 21, 2025 | marketbeat.comBraden Michael Leonard Buys 30,600 Shares of Adverum Biotechnologies, Inc. (NASDAQ:ADVM) StockMarch 21, 2025 | insidertrades.comRegeneron Pharmaceuticals Inc. Takes $845,000 Position in Adverum Biotechnologies, Inc. (NASDAQ:ADVM)Regeneron Pharmaceuticals Inc. purchased a new position in shares of Adverum Biotechnologies, Inc. (NASDAQ:ADVM - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 180,909 sharesMarch 11, 2025 | marketbeat.comAdverum Biotechnologies (ADVM) to Release Earnings on MondayAdverum Biotechnologies (NASDAQ:ADVM) will be releasing earnings before the market opens on Monday, March 17, Financial Modeling Prep reports.March 10, 2025 | marketbeat.comAdverum Biotechnologies Initiates ARTEMIS Phase 3 Study Evaluating Ixo-vec for Wet AMDMarch 4, 2025 | markets.businessinsider.comAdverum Biotechnologies initiates ARTEMIS studyMarch 4, 2025 | markets.businessinsider.comAdverum Biotechnologies (NASDAQ:ADVM) Shares Cross Below Two Hundred Day Moving Average - Here's What HappenedAdverum Biotechnologies (NASDAQ:ADVM) Share Price Passes Below Two Hundred Day Moving Average - What's Next?March 4, 2025 | marketbeat.comAdverum Biotechnologies Initiates ARTEMIS Phase 3 Study Evaluating Ixo-vec for Wet AMDMarch 3, 2025 | globenewswire.comAdverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 28, 2025 | globenewswire.comAdverum Biotechnologies to Participate in the Cowen 45th Annual Health Care ConferenceFebruary 25, 2025 | globenewswire.comAdverum Biotechnologies, Inc. (NASDAQ:ADVM) Receives Average Recommendation of "Moderate Buy" from AnalystsShares of Adverum Biotechnologies, Inc. (NASDAQ:ADVM - Get Free Report) have received an average rating of "Moderate Buy" from the six brokerages that are covering the stock, MarketBeat reports. One analyst has rated the stock with a hold rating and five have issued a buy rating on the company.February 24, 2025 | marketbeat.com3 US Penny Stocks With Market Caps Below $400MFebruary 19, 2025 | finance.yahoo.comAdverum Biotechnologies (NASDAQ:ADVM) Share Price Crosses Below 200-Day Moving Average - Here's What HappenedAdverum Biotechnologies (NASDAQ:ADVM) Stock Price Crosses Below 200 Day Moving Average - What's Next?February 15, 2025 | marketbeat.comADVM stock touches 52-week low at $3.95 amid sharp annual declineFebruary 13, 2025 | msn.com4D Molecular’s wAMD drug is best-in-class, says RBC, sees ‘ideal’ entry pointFebruary 11, 2025 | markets.businessinsider.comAdverum Biotechnologies to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences ConferenceFebruary 5, 2025 | globenewswire.comADVM stock touches 52-week low at $4.01 amid market challengesFebruary 4, 2025 | msn.comAdverum Biotechnologies, Inc. (NASDAQ:ADVM) Given Consensus Recommendation of "Moderate Buy" by BrokeragesAdverum Biotechnologies, Inc. (NASDAQ:ADVM - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the six ratings firms that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating and five have assigned a buy ratJanuary 30, 2025 | marketbeat.comAdverum Biotechnologies, Inc. (NASDAQ:ADVM) Receives Average Rating of "Moderate Buy" from AnalystsAdverum Biotechnologies, Inc. (NASDAQ:ADVM - Get Free Report) has received an average recommendation of "Moderate Buy" from the six analysts that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and five have assigneJanuary 5, 2025 | marketbeat.comAdverum Biotechnologies, Inc. (NASDAQ:ADVM) Sees Significant Increase in Short InterestAdverum Biotechnologies, Inc. (NASDAQ:ADVM - Get Free Report) was the recipient of a significant growth in short interest during the month of December. As of December 15th, there was short interest totalling 1,460,000 shares, a growth of 7.4% from the November 30th total of 1,360,000 shares. Approximately 13.0% of the shares of the company are short sold. Based on an average daily trading volume, of 229,600 shares, the days-to-cover ratio is presently 6.4 days.December 31, 2024 | marketbeat.comAdverum Biotechnologies (NASDAQ:ADVM) Cut to Sell at StockNews.comStockNews.com cut shares of Adverum Biotechnologies from a "hold" rating to a "sell" rating in a report on Thursday.December 19, 2024 | marketbeat.comFmr LLC Lowers Stock Holdings in Adverum Biotechnologies, Inc. (NASDAQ:ADVM)Fmr LLC reduced its position in Adverum Biotechnologies, Inc. (NASDAQ:ADVM - Free Report) by 63.2% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 234,718 shares of the biotechnology company's stock after sellingDecember 16, 2024 | marketbeat.comShort Interest in Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Drops By 11.1%Adverum Biotechnologies, Inc. (NASDAQ:ADVM - Get Free Report) was the recipient of a large decrease in short interest during the month of November. As of November 30th, there was short interest totalling 1,360,000 shares, a decrease of 11.1% from the November 15th total of 1,530,000 shares. Currently, 11.1% of the company's stock are sold short. Based on an average daily volume of 221,300 shares, the short-interest ratio is presently 6.1 days.December 15, 2024 | marketbeat.comAdverum Biotechnologies, Inc. (NASDAQ:ADVM) Receives Average Recommendation of "Moderate Buy" from BrokeragesAdverum Biotechnologies, Inc. (NASDAQ:ADVM - Get Free Report) has received an average rating of "Moderate Buy" from the six brokerages that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and five have issuedDecember 11, 2024 | marketbeat.comAdverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 6, 2024 | globenewswire.comAdverum Biotechnologies price target lowered to $16 from $20 at MizuhoNovember 23, 2024 | markets.businessinsider.comAdverum Biotechnologies, Inc.: Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)November 22, 2024 | finanznachrichten.deTruist Financial Sticks to Their Buy Rating for Adverum Biotechnologies (ADVM)November 20, 2024 | markets.businessinsider.comAdverum Biotechnologies (NASDAQ:ADVM) Receives "Buy" Rating from HC WainwrightHC Wainwright reissued a "buy" rating and issued a $30.00 target price on shares of Adverum Biotechnologies in a research note on Tuesday.November 19, 2024 | marketbeat.comAdverum Biotechnologies reports results of two trials of Ixo-vec in AMDNovember 18, 2024 | markets.businessinsider.comBuy Rating on Adverum Biotechnologies: Ixo-vec’s Promising Potential in Transforming Wet AMD TreatmentNovember 18, 2024 | markets.businessinsider.comAdverum Biotechnologies Announces Positive 52-Week LUNA and 4-Year OPTIC Results, and Provides Key Pivotal Program Design ElementsNovember 18, 2024 | markets.businessinsider.comShort Interest in Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Decreases By 5.9%Adverum Biotechnologies, Inc. (NASDAQ:ADVM - Get Free Report) saw a significant drop in short interest in October. As of October 31st, there was short interest totalling 1,600,000 shares, a drop of 5.9% from the October 15th total of 1,700,000 shares. Currently, 13.4% of the shares of the stock are sold short. Based on an average daily trading volume, of 184,100 shares, the short-interest ratio is currently 8.7 days.November 18, 2024 | marketbeat.comAdverum Biotechnologies, Inc. (NASDAQ:ADVM) Given Consensus Rating of "Moderate Buy" by AnalystsShares of Adverum Biotechnologies, Inc. (NASDAQ:ADVM - Get Free Report) have received an average rating of "Moderate Buy" from the six brokerages that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation and five have issued a buy recoNovember 16, 2024 | marketbeat.comAdverum Biotechnologies Announces Webcast to Report 52-Week LUNA Phase 2 Clinical Data and 4-Year OPTIC Clinical Data, and to Provide Key Pivotal Program Design ElementsNovember 15, 2024 | globenewswire.comAdverum Biotechnologies, Inc. (NASDAQ:ADVM) Shares Acquired by BML Capital Management LLCBML Capital Management LLC boosted its stake in Adverum Biotechnologies, Inc. (NASDAQ:ADVM - Free Report) by 15.4% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,268,064 shares of the biotechnology company's stock aNovember 12, 2024 | marketbeat.comChardan Capital Has Pessimistic View of ADVM FY2024 EarningsAdverum Biotechnologies, Inc. (NASDAQ:ADVM - Free Report) - Analysts at Chardan Capital reduced their FY2024 earnings estimates for shares of Adverum Biotechnologies in a research report issued to clients and investors on Tuesday, November 5th. Chardan Capital analyst D. Gataulin now expects thatNovember 8, 2024 | marketbeat.comWhat is HC Wainwright's Forecast for ADVM FY2024 Earnings?Adverum Biotechnologies, Inc. (NASDAQ:ADVM - Free Report) - Equities research analysts at HC Wainwright lowered their FY2024 EPS estimates for Adverum Biotechnologies in a research report issued to clients and investors on Tuesday, November 5th. HC Wainwright analyst M. Caufield now expects thatNovember 7, 2024 | marketbeat.comRBC Capital Sticks to Their Hold Rating for Adverum Biotechnologies (ADVM)November 7, 2024 | markets.businessinsider.comAdverum Biotechnologies (NASDAQ:ADVM) Price Target Cut to $10.00 by Analysts at Royal Bank of CanadaRoyal Bank of Canada cut their target price on Adverum Biotechnologies from $12.00 to $10.00 and set a "sector perform" rating for the company in a research note on Tuesday.November 5, 2024 | marketbeat.comAdverum Biotechnologies (NASDAQ:ADVM) Posts Quarterly Earnings Results, Misses Expectations By $0.10 EPSAdverum Biotechnologies (NASDAQ:ADVM - Get Free Report) released its quarterly earnings data on Monday. The biotechnology company reported ($1.30) earnings per share for the quarter, missing analysts' consensus estimates of ($1.20) by ($0.10). The company had revenue of $1.00 million for the quarter, compared to analyst estimates of $0.50 million.November 5, 2024 | marketbeat.comAdverum Biotechnologies (ADVM) Gets a Buy from TD CowenNovember 5, 2024 | markets.businessinsider.comAdverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate Highlights and Updates Anticipated MilestonesNovember 4, 2024 | globenewswire.comAssenagon Asset Management S.A. Cuts Stock Holdings in Adverum Biotechnologies, Inc. (NASDAQ:ADVM)Assenagon Asset Management S.A. reduced its stake in Adverum Biotechnologies, Inc. (NASDAQ:ADVM - Free Report) by 96.2% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,413 shares of the biNovember 4, 2024 | marketbeat.comShort Interest in Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Increases By 14.9%Adverum Biotechnologies, Inc. (NASDAQ:ADVM - Get Free Report) was the recipient of a large growth in short interest during the month of October. As of October 15th, there was short interest totalling 1,700,000 shares, a growth of 14.9% from the September 30th total of 1,480,000 shares. Based on an average daily volume of 202,200 shares, the short-interest ratio is currently 8.4 days. Currently, 12.0% of the shares of the stock are sold short.October 29, 2024 | marketbeat.comOppenheimer Keeps Their Buy Rating on Adverum Biotechnologies (ADVM)October 17, 2024 | markets.businessinsider.comPromising Potential of ADAR RNA Editing Fuels Buy RatingOctober 17, 2024 | markets.businessinsider.comAdverum Biotechnologies Appoints Jason L. Mitchell as Chief Commercial Officer as it Prepares to Initiate Pivotal ProgramOctober 16, 2024 | globenewswire.comAdverum Biotechnologies, Inc. (NASDAQ:ADVM) Short Interest Down 9.2% in SeptemberAdverum Biotechnologies, Inc. (NASDAQ:ADVM - Get Free Report) was the recipient of a large decline in short interest during the month of September. As of September 30th, there was short interest totalling 1,480,000 shares, a decline of 9.2% from the September 15th total of 1,630,000 shares. Based on an average trading volume of 279,100 shares, the days-to-cover ratio is presently 5.3 days. Currently, 10.5% of the company's shares are sold short.October 15, 2024 | marketbeat.com Remove Ads Get Adverum Biotechnologies News Delivered to You Automatically Sign up to receive the latest news and ratings for ADVM and its competitors with MarketBeat's FREE daily newsletter. Email Address ADVM Media Mentions By Week ADVM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ADVM News Sentiment▼1.950.79▲Average Medical News Sentiment ADVM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ADVM Articles This Week▼62▲ADVM Articles Average Week Remove Ads Get Adverum Biotechnologies News Delivered to You Automatically Sign up to receive the latest news and ratings for ADVM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies STOK News DNA News ZVRA News RGNX News SIGA News ERAS News HUMA News SNDL News PRTC News UPB News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ADVM) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adverum Biotechnologies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adverum Biotechnologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
